litlas
Log inCreate account

Laurence H. Baker

Active 1972–2022

75
Papers
19,890
Citations
71
h-index
74
i10-index

Citations

Citations per year for Laurence H. Baker1972: 1 citations1973: 2 citations1974: 10 citations1975: 17 citations1976: 5 citations1977: 10 citations1978: 6 citations1979: 6 citations1980: 12 citations1981: 13 citations1982: 14 citations1983: 24 citations1984: 13 citations1985: 16 citations1986: 5 citations1987: 23 citations1988: 19 citations1989: 10 citations1990: 28 citations1991: 26 citations1992: 28 citations1993: 28 citations1994: 27 citations1995: 28 citations1996: 29 citations1997: 17 citations1998: 25 citations1999: 32 citations2000: 39 citations2001: 42 citations2002: 60 citations2003: 43 citations2004: 48 citations2005: 81 citations2006: 59 citations2007: 61 citations2008: 68 citations2009: 132 citations2010: 140 citations2011: 147 citations2012: 173 citations2013: 202 citations2014: 137 citations2015: 144 citations2016: 164 citations2017: 164 citations2018: 177 citations2019: 504 citations2020: 577 citations2021: 488 citations2022: 372 citations2023: 284 citations2024: 379 citations2025: 153 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,403 citing papers, 31.9% of this breakdownChina: 573 citing papers, 7.6% of this breakdownUnited Kingdom: 520 citing papers, 6.9% of this breakdownItaly: 438 citing papers, 5.8% of this breakdownFrance: 380 citing papers, 5% of this breakdownGermany: 374 citing papers, 5% of this breakdownNetherlands: 248 citing papers, 3.3% of this breakdownCanada: 230 citing papers, 3% of this breakdownSpain: 206 citing papers, 2.7% of this breakdownJapan: 199 citing papers, 2.6% of this breakdownAustralia: 160 citing papers, 2.1% of this breakdownSwitzerland: 125 citing papers, 1.7% of this breakdown
0%31.9%Other 22.4%

Institutions

Fields

  • Medicine66.8%
  • Biochemistry, Genetics and Molecular Biology15.2%
  • Nursing7.2%
  • Health Professions2.1%
  • Immunology and Microbiology2.1%
  • Neuroscience1.3%
  • Other5.3%

Topics

  • Sarcoma Diagnosis and Treatment8.1%
  • Selenium in Biological Systems2.3%
  • Vascular Tumors and Angiosarcomas2.1%
  • Cancer Genomics and Diagnostics2%
  • Cancer Immunotherapy and Biomarkers1.8%
  • Cardiac tumors and thrombi1.7%
  • Other82%

Coauthors

All papers

Open in search
  1. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    Authors: Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Richard F. Riedel, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Scott H. Okuno, Damon R. Reed, John Crowley, Lisa H. Butterfield, Ruth Salazar, Jaime Rodriguez‐Canales, Alexander J. Lazar, Ignacio I. Wistuba, Laurence H. Baker, Robert G. Maki, Denise K. Reinke, Shreyaskumar Patel - The Lancet Oncology 2017 cited by 1,423

  2. Vitamin E and the Risk of Prostate Cancer

    Authors: Eric A. Klein, Ian M. Thompson, Catherine M. Tangen, John J. Crowley, M. Scott Lucia, Phyllis J. Goodman, Lori M. Minasian, Leslie G. Ford, Howard L. Parnes, J. Michael Gaziano, Daniel D. Karp, Michael M. Lieber, Philip Walther, Laurence Klotz, J. Kellogg Parsons, Joseph L. Chin, Amy K. Darke, Scott M. Lippman, Gary E. Goodman, Frank L. Meyskens, Laurence H. Baker - JAMA 2011 cited by 1,738

  3. Integrative clinical genomics of metastatic cancer

    Authors: Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, Pankaj Vats, Erin Cobain, Jessica Everett, Xuhong Cao, Erica Rabban, Chandan Kumar-Sinha, Victoria Raymond, Scott Schuetze, Ajjai Alva, Javed Siddiqui, Rashmi Chugh, Francis Worden, Mark M. Zalupski, Jeffrey W. Innis, Rajen J. Mody, Scott A. Tomlins, David Lucas, Laurence H. Baker, Nithya Ramnath, Ann F. Schott, Daniel F. Hayes, Joseph Vijai, Kenneth Offit, Elena M. Stoffel, J. Scott Roberts, David C. Smith, Lakshmi P. Kunju, Moshe Talpaz, Marcin Cieslik, Arul M. Chinnaiyan - Nature, Nat. 2017 cited by 938

  4. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers

    Authors: Scott M. Lippman, Eric A. Klein, Phyllis J. Goodman, M. Scott Lucia, Ian M. Thompson, Leslie G. Ford, Howard L. Parnes, Lori M. Minasian, J. Michael Gaziano, Jo Ann Hartline, J. Kellogg Parsons, James D. Bearden, E. David Crawford, Gary E. Goodman, Jaime O. Claudio, Eric Winquist, Elise D. Cook, Daniel D. Karp, Philip Walther, Michael M. Lieber, Alan R. Kristal, Amy K. Darke, Kathryn B. Arnold, Peter Ganz, Regina M. Santella, Demetrius Albanes, Philip R. Taylor, Jeffrey L. Probstfield, T. J. Jagpal, John J. Crowley, Frank L. Meyskens, Laurence H. Baker, Charles A. Coltman - JAMA 2008 cited by 2,115

  5. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

    Authors: Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel, Dennis A. Priebat, Scott H. Okuno, Brian L. Samuels, Michael Fanucchi, David C. Harmon, Scott M. Schuetze, Denise K. Reinke, Peter F. Thall, Robert S. Benjamin, Laurence H. Baker, Martee L. Hensley - Journal of Clinical Oncology 2007 cited by 733

  6. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

    Authors: Melissa Burgess, Vanessa Bolejack, Scott M. Schuetze, Brian Andrew Van Tine, Steven Attia, Richard F. Riedel, James Hu, Lara E. Davis, Scott H. Okuno, Dennis A. Priebat, Sujana Movva, Damon R. Reed, Sandra P. D’Angelo, Alexander J. Lazar, Emily Z. Keung, Denise K. Reinke, Laurence H. Baker, Robert G. Maki, Shreyaskumar Patel, Hussein Tawbi - Journal of Clinical Oncology 2019 cited by 138

  7. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

    Authors: George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Jean‐Yves Blay, Kenneth R. Hande, Mary Lou Keohan, Brian L. Samuels, Scott M. Schuetze, Claudia Lebedinsky, Yusri Elsayed, Miguel Izquierdo, Javier Gómez‐Román, Youn C. Park, Axel Le Cesne - Journal of Clinical Oncology 2009 cited by 536

  8. R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

    Authors: Alberto S. Pappo, Shreyaskumar Patel, John Crowley, Denise K. Reinke, Klaus-Peter Kuenkele, Sant P. Chawla, Guy C. Toner, Robert G. Maki, Paul A. Meyers, Rashmi Chugh, Kristen N. Ganjoo, Scott M. Schuetze, Heribert Juergens, Michael Leahy, Birgit Geoerger, Robert S. Benjamin, Lee J. Helman, Laurence H. Baker - Journal of Clinical Oncology 2011 cited by 321

  9. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Authors: Charles D. Blanke, Cathryn Rankin, George D. Demetri, Christopher W. Ryan, Margaret von Mehren, Robert S. Benjamin, A. Kevin Raymond, Vivien Bramwell, Laurence H. Baker, Robert G. Maki, Michael Tanaka, J. Randolph Hecht, Michael C. Heinrich, Christopher D.�M. Fletcher, John J. Crowley, Ernest C. Borden - Journal of Clinical Oncology 2008 cited by 1,077

  10. Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model

    Authors: Rashmi Chugh, J. Kyle Wathen, Robert G. Maki, Robert S. Benjamin, Shreyaskumar Patel, Paul A. Myers, Dennis A. Priebat, Denise K. Reinke, Dafydd G. Thomas, Mary Lou Keohan, Brian L. Samuels, Laurence H. Baker - Journal of Clinical Oncology 2009 cited by 234

  11. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

    Authors: Scott M. Schuetze, Vanessa Bolejack, Edwin Choy, Kristen N. Ganjoo, Arthur P. Staddon, Warren Chow, Hussein A. Tawbi, Brian L. Samuels, Shreyaskumar Patel, Margaret von Mehren, Gina Z. D’Amato, Kirsten Leu, David M. Loeb, Charles Forscher, Mohammed Milhem, Daniel A. Rushing, David R. Lucas, Rashmi Chugh, Denise K. Reinke, Laurence H. Baker - Cancer 2016 cited by 132

  12. SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

    Authors: Scott M. Schuetze, J. Kyle Wathen, David R. Lucas, Edwin Choy, Brian L. Samuels, Arthur P. Staddon, Kristen N. Ganjoo, Margaret von Mehren, Warren Chow, David M. Loeb, Hussein A. Tawbi, Daniel A. Rushing, Shreyaskumar Patel, Dafydd G. Thomas, Rashmi Chugh, Denise K. Reinke, Laurence H. Baker - Cancer 2015 cited by 108

  13. Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

    Authors: Rashmi Chugh, J. Kyle Wathen, Shreyaskumar Patel, Robert G. Maki, Paul A. Meyers, Scott M. Schuetze, Dennis A. Priebat, Dafydd G. Thomas, Jon A. Jacobson, Brian L. Samuels, Robert S. Benjamin, Laurence H. Baker - Clinical Cancer Research 2010 cited by 237

  14. Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

    Authors: Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Scott M. Schuetze, Anthony W. Tolcher, Gina Z. D’Amato, Jean‐Yves Blay, Monica Mita, Kamalesh K. Sankhala, Lori Berk, Victor M. Rivera, Tim Clackson, John W. Loewy, Frank G. Haluska, George D. Demetri - Journal of Clinical Oncology 2011 cited by 247

  15. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

    Authors: Hemant K. Bid, Doris A. Phelps, Linlin Xaio, Denis C. Guttridge, Jiayuh Lin, Cheryl A. London, Laurence H. Baker, Xiaokui Mo, Peter J. Houghton - Molecular Cancer Therapeutics 2016 cited by 90

  16. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas

    Authors: Inga‐Marie Schaefer, Meijun Z. Lundberg, Elizabeth G. Demicco, Joanna Przybył, Magdalena Matusiak, Frédéric Chibon, Davis R. Ingram, Jason L. Hornick, Wei‐Lien Wang, Sebastian Bauer, Laurence H. Baker, Alexander J. Lazar, Matt van de Rijn, Adrián Mariño‐Enríquez, Jonathan A. Fletcher - Cancer 2021 cited by 35

  17. Chordoma: The Nonsarcoma Primary Bone Tumor

    Authors: Rashmi Chugh, Hussein Tawbi, David R. Lucas, J. Sybil Biermann, Scott M. Schuetze, Laurence H. Baker - The Oncologist 2007 cited by 394

  18. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

    Authors: E. Robert Greenberg, Garnet L. Anderson, Douglas R. Morgan, Javier Torres, William D. Chey, Luis Eduardo Bravo, Ricardo L. Domínguez, Catterina Ferreccio, Rolando Herrero, Eduardo Lazcano‐Ponce, María Mercedes Meza‐Montenegro, Rodolfo Peña, Edgar M. Peña-Galo, Eduardo Salazar-Martínez, Pelayo Correa, M. Elena Martinez, Manuel Valdivieso, Gary E. Goodman, John J. Crowley, Laurence H. Baker - The Lancet 2011 cited by 255

  19. Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma

    Authors: Martee L. Hensley, J. Kyle Wathen, Robert G. Maki, Dejka M. Araujo, Gregory P. Sutton, Dennis A. Priebat, Suzanne George, Robert A. Soslow, Laurence H. Baker - Cancer 2013 cited by 171

  20. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results

    Authors: Michael C. Heinrich, Cathryn Rankin, Charles D. Blanke, George D. Demetri, Ernest C. Borden, Christopher W. Ryan, Margaret von Mehren, Martin E. Blackstein, Dennis A. Priebat, William D. Tap, Robert G. Maki, Christopher L. Corless, Jonathan A. Fletcher, Kouros Owzar, John J. Crowley, Robert S. Benjamin, Laurence H. Baker - JAMA Oncology 2017 cited by 126

  21. When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

    Authors: Geoffrey R. Oxnard, Michael J. Morris, F. Stephen Hodi, Laurence H. Baker, Mark G. Kris, Alan P. Venook, Lawrence H. Schwartz - JNCI Journal of the National Cancer Institute 2012 cited by 124

  22. Cutaneous angiosarcoma of the scalp

    Authors: Timothy M. Pawlik, Augusto F. G. Paulino, Cornelius J. McGinn, Laurence H. Baker, Deborah S. Cohen, Jeffery S. Morris, Riley S. Rees, Vernon K. Sondak - Cancer 2003 cited by 342

  23. Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma

    Authors: Kirsten Leu, Leo J. Ostruszka, Donna S. Shewach, Mark M. Zalupski, Vernon K. Sondak, J. Sybil Biermann, Julia Shin-Jung Lee, Carol Couwlier, Krisinda Palazzolo, Laurence H. Baker - Journal of Clinical Oncology 2004 cited by 245

  24. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy

    Authors: Lawrence Leichman, Norman D. Nigro, Vainutis K. Vaitkevicius, Basil Considine, T Buroker, G. Bradley, H. Gunter Seydel, Steven Olchowski, Glenn Cummings, Cynthia G. Leichman, Laurence H. Baker - The American Journal of Medicine 1985 cited by 219